A Prospective, Open-ended, Multi-center Study of Schizophrenia Patients Switching to Zolodine

Summary

Through self-controlled studies on metabolic syndrome related indicators, efficacy and other adverse reactions in patients with schizophrenia who developed metabolic syndrome after treatment with other antipsychotics, switched to Zoladine capsules (ziprasidone hydrochloride capsules). To evaluate the clinical application value of switching to Zolodine for schizophrenia patients with metabolic syndrome, and to explore the drug selection strategy for long-term treatment of schizophrenia patients.

Timeline

Start

2012-01-01

Primary completion

2012-07-01

Completion

2012-07-01

Drugs

Indications